{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:34:30Z","timestamp":1718757270226},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1705","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>The FDA has approved a 0.25% ophthalmic solution of the ectoparasiticide lotilaner (Xdemvy \u2013 Tarsus) for treatment of Demodex blepharitis. Lotilaner is the first drug to be approved in the US for this indication.<\/jats:p>","DOI":"10.58347\/tml.2024.1705b","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T17:01:16Z","timestamp":1718730076000},"page":"99-100","source":"Crossref","is-referenced-by-count":0,"title":["Lotilaner (Xdemvy) for Demodex Blepharitis"],"prefix":"10.58347","volume":"66","member":"37151","published-online":{"date-parts":[[2024,6,24]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T17:01:16Z","timestamp":1718730076000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1705b"}},"subtitle":[],"editor":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,6,24]]},"references-count":0,"journal-issue":{"issue":"1705","published-online":{"date-parts":[[2024,6,24]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2024.1705b","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,24]]}}}